Richard L. Md Lindstrom Acquires 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, May 8th. The stock was acquired at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Ocular Therapeutix Stock Down 1.0%

OCUL opened at $6.93 on Thursday. The company has a fifty day moving average price of $7.44 and a 200-day moving average price of $8.21. The firm has a market capitalization of $1.10 billion, a P/E ratio of -5.25 and a beta of 1.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a one year low of $4.79 and a one year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Institutional Trading of Ocular Therapeutix

A number of hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC lifted its holdings in shares of Ocular Therapeutix by 8.1% during the 1st quarter. Hsbc Holdings PLC now owns 19,573 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 1,472 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Ocular Therapeutix by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company’s stock worth $792,000 after acquiring an additional 2,454 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Ocular Therapeutix by 10.0% during the 4th quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,526 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Ocular Therapeutix by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company’s stock worth $755,000 after acquiring an additional 2,853 shares during the last quarter. Finally, Brooklyn Investment Group lifted its holdings in shares of Ocular Therapeutix by 151.5% during the 1st quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 3,155 shares during the last quarter. 59.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OCUL has been the subject of a number of recent research reports. Needham & Company LLC reduced their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an “outperform” rating for the company. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price target for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.25.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.